Individuals with metabolic syndrome (MetS) often have elevated plasma plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA), contributing to an increased risk of cardiovascular disease. PAI-1 and t-PA may be affected by chronic (n-3) long-chain PUFA [(n-3)LCPUFA] supplementation; however, the acute impact of fat ingestion on these risk factors has not been established. Our objective was to investigate the acute effect of (n-3)LCPUFA on plasma PAI-1, t-PA, and platelet aggregation. We conducted a randomized crossover study in which men (n = 8, $45 y) with MetS consumed water or a high-saturated fat beverage (1 g fat/kg body weight) with either a high or low content of (n-3)
Introduction
(n-3) Long-chain PUFA [(n-3)LCPUFA 5 ] have been shown to effectively reduce blood pressure and elevated plasma triacylglycerol (TAG) concentrations, 2 of the diagnostic criteria for metabolic syndrome (MetS) (1, 2) . MetS also includes abdominal obesity, decreased HDL-cholesterol, and hyperglycemia, all of which may contribute to the onset of type 2 diabetes and cardiovascular disease (CVD) (3) . As well as specific MetS diagnostic criteria, a number of other CVD biomarkers have also been shown to be elevated in individuals with MetS, including factors involved in the hemostatic system, such as plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) (4) that increase the risk of platelet aggregation. PAI-1 and t-PA have also been associated with increased risk of type 2 diabetes and CVD (5, 6) .
Both chronic and postprandial hypertriacylglyceridemia may be a procoagulant state involving disturbances of the hemostatic system (5, 7) . In particular, fat ingestion has been associated with both elevated blood TAG and increased PAI-1 activity in humans (8) . In vitro studies have demonstrated that fatty acids with different degrees of saturation alter PAI-1 secretion and mRNA levels (9, 10) , suggesting that the type of fat ingested plays a role in altering fibrinolytic biomarkers. (n-3)LCPUFA have been shown to reduce the postprandial TAG response (11) (12) (13) and this may be one mechanism by which (n-3)LCPUFA affect the hemodynamic system, because postprandial lipemia may affect PAI-1 and t-PA (7, 14) . Hence, it may be important to consider how postprandial PAI-1 and t-PA are affected by (n-3)LCPUFA.
Most studies investigating the effect of dietary fat, including (n-3)LCPUFA, on plasma PAI-1 and t-PA and platelet aggregation have been conducted in the fasted state. Some studies indicate that (n-3)LCPUFA may affect fasting PAI-1 and t-PA (15) (16) (17) (18) (19) (20) (21) (22) , but overall the studies are not conclusive. Fasting levels of hemostatic variables are good predictors of CVD risk (23) (24) (25) and it is plausible that postprandial PAI-1 and t-PA concentrations may also be useful MetS biomarkers. To our knowledge, no studies have investigated whether (n-3)LCPUFA can influence PAI-1 and t-PA in the postprandial state. Thus, the primary objective of the present study was to investigate the acute effect of (n-3)LCPUFA on PAI-1, t-PA, and platelet aggregation. To do this, men with MetS ingested a saturated fat-rich beverage with either a high or low amount of (n-3)LCPUFA or water in a randomized crossover study.
Methods
Participants and preliminary screening. This study was approved by the University of Guelph Research Ethics Board and all participants provided informed, written consent. Men $45 y were recruited from Guelph, ON and surrounding communities using newspaper advertisements. Potential participants were screened for type 2 diabetes using a standard 2-h oral glucose tolerance test (Trutol Custom Laboratories) and fasting glucose, TAG, and HDL-cholesterol were analyzed, along with participant height, weight, BMI, waist circumference, and blood pressure. Only men who met $3 ATP III criteria for MetS were included in the study (1) . Participants taking antihypertensive medication were considered to meet the ATP III hypertension criteria. Individuals were excluded if they smoked, used lipid-lowering or antiinflammatory medication, used medication to control diabetes, had any disease or condition known to affect study endpoints, or were making conscious efforts to increase their (n-3) fatty acid intake through diet or supplements that they were not willing to discontinue for a mandatory 4-wk prestudy washout period and study duration. Individuals were also excluded if they had a BMI ,25 kg/m 2 , were dieting, had significant weight gain or loss (6 6 kg) within the last 6 mo, or were physically active (.30 min, 3 d/wk of moderate physical activity). Five participants were taking blood pressure-lowering medication and 3 were taking antidepressants. Intake of medication was constant throughout the study. One participant had been prescribed an antiinflammatory drug on an as-needed basis but agreed to refrain from using this medication during the study period. One participant took low dose aspirin, but no aspirin was taken 48 h prior to a study day and the responses of this participant did not differ from the others. Eight men completed the study. A sample size calculation (P = 0.05; power = 0.8) for TAG area under the curve (AUC) revealed that n = 8 or 9 was sufficient to demonstrate significant differences between the high (n-3) oral fat tolerance test (OFTT) vs. water and low (n-3) OFTT vs. water, respectively. Study design. This study used a randomized crossover design that consisted of 3 study days, each separated by a 1-wk washout period as described (26) . We have previously demonstrated that 1 wk between acute fat loads is sufficient to eliminate carry-over effects in blood measurements (26, 27) . Participants were asked to avoid consumption of any dietary supplements, antioxidants, or (n-3)LCPUFA-rich products for 2 wk before and throughout the study period. Food records were completed by each participant for the 3 d before each study day (analyzed by ESHA Food Processor 9.5). Participants were required to abstain from alcohol, caffeine, and exercise for 48 h prior to each study day. Participants consumed a provided meal (2299 kJ, 13.1% protein, 52.4% carbohydrate, 17.2% fat) at home the evening before each study day, followed by a 12-h fast (water was allowed). Upon arrival at the laboratory, a Teflon catheter was inserted into a forearm vein. After a fasting blood sample was taken (0 h), participants ingested either an OFTT (1 g fat/kg body weight) with a high or low content of (n-3) LCPUFA or an equal volume of water. Postprandial blood samples were collected every second hour throughout the following 8 h.
OFTT. The OFTT were prepared in the laboratory according to Dekker et al. (27) with modifications, as previously reported (26) . Briefly, the fat loads were devoid of protein and carbohydrate and contained either a high or low amount of (n-3)LCPUFA such that the beverage had a ratio of (n-6):(n-3) fatty acids of~3:1 and 18:1, respectively, and a constant amount of PUFA, monounsaturated fatty acid, and SFA. Palm stearin (57% 16:0, palmitic acid) (Bunge Canada) and safflower oil (65% 18:2 (n-6), linoleic acid) (President's Choice, purchased at Zehrs Markets) were the primary sources of SFA and (n-6) PUFA, respectively. Refined fish oil concentrate [48% 20:5(n-3), eicosapentaenoic acid; 25% 22:6(n-3), docosahexaenoic acid] (generously provided by Ocean Nutrition Canada) was the source of (n-3)LCPUFA. For OFTT preparation, palm stearin was mixed with safflower oil prior to the trial day and stored at 2208C. On the morning of each study day, fish oil and emulsifying agents (Myverol, 2% of fat and Tween, 0.15% of fat, 1899K and Polysorbate 80K, 1.2%, respectively, Acatris) were added to the fat mixture, flavored, and colored as previously described (26) . The fatty acid composition of the 2 fat loads was analyzed by GLC ( Table 1) .
Whole blood glucose and lipids and serum insulin. Whole blood glucose and lipids, including TAG, total cholesterol, HDL-cholesterol, and LDL-cholesterol, were measured in samples taken from the men after a 12-h fast, as well as in samples taken every 2 h over 8 h, as previously described in detail (26) . Serum insulin was measured in samples taken from participants after a 12-h fast as previously described in detail (26) .
Plasma PAI-1 and t-PA. Blood was collected after a 12-h fast and every 2 h over 8 h in glass 3.2% sodium citrate tubes (BD Vacutainer, Preanalytical Solutions) to determine the concentrations of PAI-1 and t-PA and PAI-1 activity. For determination of t-PA activity, blood was collected in Stabilyte tubes (Biopool Stabilyte tube, Trinity Biotech) containing 0.5 mmol/L sodium citrate (pH 4.3) to prevent complex formation of PAI-1 and t-PA. All tubes were centrifuged at 3000 3 g for 20 min at 48C and plasma was stored at 2808C until analysis. Plasma concentrations of PAI-1 and t-PA were determined in duplicate by ELISA (Biopool TintElize, Trinity Biotech). PAI-1 and t-PA activity were determined by bioassay (Chromolize, Trinity Biotech). The intra-and inter-assay CV were 1.9 and 2.4% for PAI-1 concentration, 2.7 and 4.6% for PAI-1 activity, 5.5 and 3.5% for t-PA concentration, and 7.0 and 5.3% for t-PA activity, respectively, as reported by the manufacturer.
Platelet aggregation. Blood was collected in plastic 3.2% sodium citrate tubes (BD Vacutainer), mixed carefully to avoid activation of the platelets, and kept in a 378C water bath before analysis in duplicate. Whole blood (0.5 mL) was diluted with 0.5 mL of room temperature saline in a cuvette. The dilution was kept in the aggregometer for 5 min (378C) and stirred (300 3 g) for an additional 5 min. ADP (20 mL, dissolved in isotonic saline and stored at 2208C) and collagen (5 mL, undiluted, stored at 2-88C) (Chrono-par ADP and collagen reagent, Chrono-log) were used as aggregation agents and added during stirring. The first and second runs of platelet aggregation were performed within 30 min and 1 h after blood withdrawal, respectively.
Statistical analysis. Samples with values .4 SD from the mean were considered outliers and were eliminated from statistical analysis. TAG, PAI-1, and t-PA concentrations were transformed using the natural logarithm to normalize the distribution prior to statistical analysis and were subsequently reverse transformed and presented as geometric mean 6 SEM. D-Values were calculated by subtracting the natural logarithmtransformed baseline values (0 h) of each participant from each time point within each treatment. The fat responses were compared by a 2-way repeated-measures ANOVA with treatment, time point, and participant as variables and baseline value as a covariate. All treatment by time interactions were nonsignificant and were removed from the analysis before the final statistic computation. The AUC for each treatment was calculated using GraphPad Prism version 4.0 (GraphPad Software) and analyzed by a 2-way ANOVA with treatment and participant as variables. All statistical procedures were performed using SAS (version 9.1, SAS institute) with significance set at P , 0.05.
Results
Participant characteristics. Participant physical and clinical characteristics at study entry have been previously described in detail (26) ( Table 2) . Energy, carbohydrate, protein, total fat, saturated fat, dietary fiber, alcohol, and caffeine intake did not differ between any of the study days (data not shown).
Blood TAG and glucose. As expected, blood TAG increased during the 8-h postprandial period in response to the 2 fat loads, regardless of the (n-3)LCPUFA content, whereas there was no change in blood TAG after water ingestion (Fig. 1) . Neither the overall TAG response nor TAG AUC (data not shown) differed between the 2 fat treatments. Blood glucose decreased significantly in the postprandial state, but there were no differences between treatments (data not shown).
Fibrinolytic measurements. The 3 study days did not differ in fasting (0 h) concentration and activity of PAI-1 or in the activity of t-PA. However, the fasting concentration of t-PA did vary among the 3 study days. The fasting PAI-1 concentration (35.6 mg/L) and activity (37.4 kIU/L) and the t-PA concentration (9.1 mg/L) were elevated, whereas t-PA activity (0.27 kIU/L) was lower compared with the normal ranges reported for healthy individuals and as expected in those with MetS (6, 19, 28) . During the 8-h postprandial period, there were significant decreases in the concentrations of PAI-1 and t-PA and in the activity of PAI-1, as well as a significant increase in the activity of t-PA after ingestion of either of the fat beverages or water. Although we calculated AUC for both PAI-1 and t-PA, it is noteworthy that these data must be interpreted with caution given that these responses did not return to baseline over the time frame (8 h) studied. Overall, the circulating concentration and activity of PAI-1 were both higher after the high compared with the low (n-3)LCPUFA load (P , 0.05) ( Fig. 2A,B) . However, fat treatment did not significantly affect the PAI-1 concentration at specific time points or the PAI-1 AUC (data not shown). Also, there were no differences in the concentration of PAI-1 between either of the fat loads and water ( Fig. 2A) . The overall difference in PAI-1 activity between the 2 fat loads was supported by a tendency for a higher PAI-1 activity at 6 h (P = 0.09; Fig. 2B ), but the AUC for PAI-1 activity was not affected by treatment (P = 0.11; data not shown). Furthermore, the activity of PAI-1 after the high (n-3)LCPUFA load was greater (P , 0.05) than that after water, whereas PAI-1 activity did not differ after consumption of the low (n-3)LCPUFA beverage and water (Fig. 2B) .
The t-PA activity after ingestion of the high (n-3)LCPUFA beverage was lower compared with the low (n-3)LCPUFA beverage (P , 0.05; Fig. 2D ) in agreement with the overall differences of PAI-1, indicating a lower activity of fibrinolysis. However, t-PA activity did not differ at specific time points or in the t-PA AUC (data not shown). There were no significant effects of treatment on the t-PA concentration (Fig. 2C) . 1 Data are means 6 SEM, n = 8 and were measured in men after a 12-h fast at study entry. 2 Data are means 6 SEM, n = 8 means of the 3 baseline values measured on the 3 trial days in men after a 12-h fast in whole blood (glucose and lipids), serum (insulin), and plasma (PAI-1 and t-PA). Platelet aggregation. Fasting (0 h) platelet aggregation did not differ between any of the treatments with the exception of the 0 h values (when aggregation was stimulated with ADP) before the low (n-3)LCPUFA load compared with those before water ingestion (data not shown). There was no change in platelet aggregation over 8 h after any of the treatments (data not shown). Furthermore, ADP and collagen-induced platelet aggregation did not differ when men received the fat treatments (data not shown).
Discussion
Previous research has shown that chronic (n-3)LCPUFA intake improves several CVD biomarkers, including plasma lipid profile, primarily characterized by a decrease in TAG (1,2). Improvement in CVD risk is especially critical in individuals with MetS and dietary (n-3)LCPUFA may provide a valuable prevention strategy. There is limited research on acute effects of (n-3)LCPUFA on CVD biomarkers and to our knowledge, we are the first to examine the postprandial effects of oral fat loads varying in (n-3)LCPUFA content on thrombotic risk markers, PAI-1 and t-PA, and platelet aggregation. Overall, our participants had PAI-1 and t-PA concentrations above those reported for healthy individuals (6, 19, 28) , although the lack of a healthy control group is a limitation of the current study and precludes a specific discussion on the impact of MetS per se. Interestingly, we found that acute ingestion of a high compared with low (n-3)LCPUFA load resulted in a decreased ability for fibrinolysis, as assessed by a higher PAI-1 concentration and activity, and a lower t-PA activity, suggesting that acute (n-3)LCPUFA ingestion may not have the same beneficial effects as long-term (n-3)LCPUFA supplementation. Elevated blood TAG following a high-fat load provides a physiological basis for alterations in some CVD biomarkers, including fibrinolytic parameters. TAG is a major component of liver-derived VLDL and studies have shown that VLDL, especially in hypertriglyceridemic individuals, can stimulate PAI-1 in human endothelial cells in vitro (29, 30) and rat endothelial cells in vivo (31) . This could provide a mechanistic pathway for an effect of (n-3)LCPUFA on fibrinolytic measurements. In the present study, TAG increased in response to both OFTT, but was not affected by fat load composition. Although an increase in TAG concentration could potentially contribute to an increase in plasma PAI-1, such a mechanism may not occur over 8 h.
PAI-1 concentration and activity decreased during the day in all treatments, including water, in accordance with expected diurnal variation (32) . Overall, we observed a significantly reduced decrease in PAI-1 concentration and activity following the high compared with low (n-3)LCPUFA load. Most long-term (n-3)LCPUFA supplementation studies have found an increase in fasting PAI-1 concentrations (15) (16) (17) (18) (19) (20) , although a few studies have found the opposite effect (21, 22) . Little research has examined the acute effect of (n-3)LCPUFA despite the fact that we spend up to 18 h/d in the postprandial state and this period has been associated with CVD risk. Ours is the only study that has investigated the postprandial impact of (n-3)LCPUFA on PAI-1, but other postprandial studies investigating different types of fatty acids over 8 h have shown a tendency toward an increase in circulating PAI-1 following unsaturated fatty acids consumption compared with SFA (7). Our results are further supported by in vitro studies showing that (n-3)LCPUFA can increase both PAI-1 secretion (9) and expression of PAI-1 mRNA (10). However, more studies are needed to elucidate the acute effect of (n-3)LCPUFA on PAI-1 in vivo.
PAI-1 is the major inhibitor of fibrinolytic activity and prevents t-PA from cleaving inactive plasminogen to the active plasmin compound by forming a complex with t-PA. We found that t-PA concentration decreased, while the activity of t-PA increased, during the day after all treatments. Whereas the (n-3) Long-chain polyunsaturated fatty acids and fibrinolysis 41 increase in t-PA activity was reduced following ingestion of the high compared with low (n-3)LCPUFA load, there was no difference due to fat composition for t-PA concentration. Based on our finding that acute (n-3)LCPUFA ingestion increases PAI-1 concentration, we would have expected an increase in t-PA concentration, as t-PA concentration tends to follow PAI-1 concentration because of their complex formation (28, 33) . Although we cannot explain the disconnect between t-PA concentration and activity without further study, the low activity of t-PA reflects a reduced ability of fibrinolysis, suggesting that acute (n-3)LCPUFA ingestion might decrease postprandial fibrinolytic activity in men with MetS. We are aware of only 1 other study that has investigated the postprandial effect of (n-3)LCPUFA on t-PA activity (13) and, contrary to our findings, it reported no change in t-PA. However, Marckmann et al. (13) examined the effect of fish oil in a breakfast meal, followed by a second meal, making our study designs very different. Another postprandial study that supports our findings showed that t-PA activity over 8 h was significantly lower after a meal with unsaturated fatty acids compared with SFA (7); however, (n-3)LCPUFA were not included.
Platelet aggregation is another thrombotic risk marker that has been well studied in relation to dietary (n-3)LCPUFA. We found no change in either ADP-or collagen-induced platelet aggregation following ingestion of either OFTT or water, which is in accordance with a previous study focused on acute (n-3) LCPUFA ingestion (34) . Taken together, this suggests that it may not be possible to achieve acute changes in platelet aggregation after ingestion of a single fat load.
A strength of our study is that, despite the small sample size, we successfully recruited men with MetS who were already at high CVD risk (3, 35, 36) and thus may have shown augmented responses to dietary intervention. Also, we used an OFTT devoid of protein and carbohydrate to isolate the effect of (n-3) LCPUFA. It is noteworthy, however, that because we altered the (n-6):(n-3) fatty acid ratio in the OFTT, we are unable to attribute any observed differences solely to the effects of (n-3) LCPUFA per se. That is, to keep the amount of PUFA constant, the low (n-3)LCPUFA beverage contained (n-6) PUFA and it is conceivable that this might also have affected the results, although this requires further study in an acute postprandial model.
Overall, a shift in the balance between plasma PAI-1 and t-PA, indicated by an increase in the concentration and activity of PAI-1 along with a decrease in t-PA activity, suggests a decreased ability of fibrinolysis in response to acute (n-3) LCPUFA ingestion. This potentially negative effect of (n-3) LCPUFA in the postprandial state is contradictory to the marked reduction in CVD mortality and morbidity observed in prospective studies following chronic consumption of high amounts of fish oil (37) (38) (39) . Thus, our findings indicate that, with respect to fibrinolytic measurements, acute and chronic intake of fish oil may show opposite effects, although the underlying mechanistic basis for this is not understood. Considering that we spend considerable time in the postprandial state, the impact of acute (n-3)LCPUFA intake should be further studied in this population compared with a healthy control group.
